DE60236522D1 - G-csf konjugate - Google Patents

G-csf konjugate

Info

Publication number
DE60236522D1
DE60236522D1 DE60236522T DE60236522T DE60236522D1 DE 60236522 D1 DE60236522 D1 DE 60236522D1 DE 60236522 T DE60236522 T DE 60236522T DE 60236522 T DE60236522 T DE 60236522T DE 60236522 D1 DE60236522 D1 DE 60236522D1
Authority
DE
Germany
Prior art keywords
csf
conjugates
lysine residue
polypeptide
conjugated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60236522T
Other languages
English (en)
Inventor
Torben Lauesgaard Nissen
Kim Vilbour Andersen
Christian Karsten Hansen
Jan Moeller Mikkelsen
Hans Thalsgaerd Schambye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxygen Inc
Original Assignee
Maxygen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27222576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60236522(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/904,196 external-priority patent/US6555660B2/en
Application filed by Maxygen Inc filed Critical Maxygen Inc
Application granted granted Critical
Publication of DE60236522D1 publication Critical patent/DE60236522D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
DE60236522T 2001-07-11 2002-07-10 G-csf konjugate Expired - Lifetime DE60236522D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/904,196 US6555660B2 (en) 2000-01-10 2001-07-11 G-CSF conjugates
DKPA200200447 2002-03-22
DKPA200200708 2002-05-08
PCT/DK2002/000482 WO2003006501A2 (en) 2001-07-11 2002-07-10 G-csf conjugates

Publications (1)

Publication Number Publication Date
DE60236522D1 true DE60236522D1 (de) 2010-07-08

Family

ID=27222576

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60236522T Expired - Lifetime DE60236522D1 (de) 2001-07-11 2002-07-10 G-csf konjugate

Country Status (16)

Country Link
US (4) US7550565B2 (de)
EP (1) EP1425304B9 (de)
JP (1) JP4444652B2 (de)
KR (1) KR100961859B1 (de)
AT (1) ATE468862T1 (de)
AU (1) AU2002325819B2 (de)
BR (1) BR0211071A (de)
CA (1) CA2452582C (de)
DE (1) DE60236522D1 (de)
HU (1) HUP0400466A3 (de)
IL (1) IL159524A0 (de)
MX (1) MXPA04000231A (de)
NO (1) NO20040093L (de)
NZ (1) NZ530545A (de)
PL (1) PL371781A1 (de)
WO (1) WO2003006501A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
AU2004236174B2 (en) 2001-10-10 2011-06-02 Novo Nordisk A/S Glycopegylation methods and proteins/peptides produced by the methods
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20060228331A1 (en) * 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
WO2005035565A1 (en) * 2003-10-10 2005-04-21 Novo Nordisk A/S Il-21 derivatives
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
NZ547554A (en) * 2003-12-03 2009-09-25 Biogenerix Ag Glycopegylated granulocyte colony stimulating factor
EP1586334A1 (de) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF Konjugate mit PEG
EP1814573B1 (de) 2004-10-29 2016-03-09 ratiopharm GmbH Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf)
CA2586365A1 (en) 2004-11-05 2006-05-26 Northwestern University Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders
JP2006137678A (ja) * 2004-11-10 2006-06-01 Shionogi & Co Ltd インターロイキン−２組成物
NZ556436A (en) 2005-01-10 2010-11-26 Biogenerix Ag Glycopegylated granulocyte colony stimulating factor
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
BRPI0611221A2 (pt) * 2005-06-01 2010-08-24 Maxygen Holdings Ltd polipeptÍdeos de g-csf peguilados e mÉtodos de produÇço dos mesmos
KR100694994B1 (ko) 2005-06-13 2007-03-14 씨제이 주식회사 사람 과립구 콜로니 형성인자 동종체
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007049941A1 (en) * 2005-10-27 2007-05-03 Peptron Co., Ltd Bioactive substance carrier for in vivo stable delivery tehreof, conjugate containing the same, and method of in vivo stable delivery of the bioactive substance
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
MY150687A (en) 2006-07-21 2014-02-28 Femalon S P R L Assay and kit for predicting implantation success in assisted fertilisation
US9176145B2 (en) 2006-07-21 2015-11-03 Femalon S.P.R.L. Kit for predicting implantation success in assisted fertilization
JP2009544327A (ja) 2006-07-21 2009-12-17 ノヴォ ノルディスク アー／エス Ｏ−結合型グリコシル化配列によるペプチドのグリコシル化
EP2049149B1 (de) * 2006-07-31 2015-04-15 Novo Nordisk A/S Pegylierte verlängerte insuline
ITMI20061624A1 (it) * 2006-08-11 2008-02-12 Bioker Srl Mono-coniugati sito-specifici di g-csf
JP2010505874A (ja) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー／エス ポリペプチドコンジュゲートの精製方法
KR20150064246A (ko) 2007-04-03 2015-06-10 바이오제너릭스 게엠베하 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
JP5876649B2 (ja) 2007-06-12 2016-03-02 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ ヌクレオチド糖の改良製造法
CN103497246B (zh) 2008-02-27 2016-08-10 诺沃—诺迪斯克有限公司 缀合的因子viii分子
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
CN102215876A (zh) * 2008-09-19 2011-10-12 马克西根公司 通过施用多peg化的粒细胞集落刺激因子(g-csf)变体来治疗辐射诱发的嗜中性细胞减少症的方法
CN102625811B (zh) 2008-10-10 2016-09-21 安姆根有限公司 Fgf21突变体及其用途
EP2427207B1 (de) 2009-05-05 2017-08-16 Amgen, Inc Fgf21-mutanten und ihre verwendungen
EA021425B1 (ru) 2009-05-05 2015-06-30 Амген Инк. Мутанты fgf21 и их применение
MX2011013903A (es) * 2009-06-17 2012-05-08 Amgen Inc Polipeptidos quimericos y usos de los mismos.
US8450086B2 (en) 2009-11-17 2013-05-28 Centocor Ortho Biotech Inc. Bacterial membrane protein secretion
MX2012006397A (es) 2009-12-02 2012-11-30 Amgen Inc PROTEINAS DE ENLACE QUE ENLAZAN A FGFR1C HUMANO, ß-KLOTHO HUMANA Y TANTO FGFR1C HUMANO COMO ß-KLOTHO HUMANA.
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
CN102906108B (zh) 2010-03-04 2016-01-20 菲尼克斯公司 用于无变性制备可溶性重组干扰素蛋白的方法
PL2552949T3 (pl) 2010-04-01 2017-01-31 Pfenex Inc. Sposoby wytwarzania G-CSF w komórce gospodarza Pseudomonas
US9517264B2 (en) 2010-04-15 2016-12-13 Amgen Inc. Human FGF receptor and β-Klotho binding proteins
US9320777B2 (en) * 2011-05-13 2016-04-26 Bolder Biotechnology, Inc. Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure
KR101623906B1 (ko) * 2014-07-23 2016-05-24 주식회사 이큐스앤자루 과립구 콜로니 자극인자 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물
WO2016013725A1 (ko) * 2014-07-23 2016-01-28 주식회사 이큐스앤자루 과립구 콜로니 자극인자 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물
SG11201700629TA (en) * 2014-08-11 2017-02-27 Delinia Inc Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
KR101950916B1 (ko) * 2014-09-10 2019-02-21 크링글파마 가부시키가이샤 신경 질환의 치료에 적절한 hgf 제제
US20160361426A1 (en) * 2015-06-11 2016-12-15 Prolong Pharmaceuticals, LLC Pegylated granulocyte colony stimulating factor (gcsf)
US11229683B2 (en) 2015-09-18 2022-01-25 Bolder Biotechnology, Inc. Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
SG11201903882VA (en) 2016-11-08 2019-05-30 Delinia Inc Il-2 variants for the treatment of autoimmune diseases

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3209596C2 (de) * 1982-03-17 1985-10-03 Uni-Cardan Ag, 5200 Siegburg Gleichlaufdrehgelenk
WO1985000817A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
JPS61227526A (ja) 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
WO1986004605A1 (en) 1985-02-08 1986-08-14 Chugai Seiyaku Kabushiki Kaisha Human granulocyte colony stimulating factor
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US6004548A (en) * 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
JPS6263335A (ja) 1985-09-13 1987-03-20 Fuji Photo Film Co Ltd 化学反応情報の処理方法
EP0220520B1 (de) 1985-09-30 1991-09-18 Chugai Seiyaku Kabushiki Kaisha Menschlicher Granulozyten-Colony stimulierender Faktor
EP0230980B2 (de) 1986-01-22 1996-03-20 Chugai Seiyaku Kabushiki Kaisha Pharmazeutischer Stoff für die Förderung der Wiederherstellung der hämatopoietischen Fähigkeit
US4908773A (en) * 1987-04-06 1990-03-13 Genex Corporation Computer designed stabilized proteins and method for producing same
DK203187A (da) 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
WO1988001297A1 (en) 1986-08-11 1988-02-25 Cetus Corporation Expression of g-csf and muteins thereof
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5214132A (en) * 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
NO176799C (no) 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
US5362853A (en) * 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5681720A (en) 1986-12-23 1997-10-28 Kyowa Hakko Co., Ltd. DNA encoding human granulocyte colony stimulating factor plasmids and host cells comprising same, and methods of expressing the encoded polypeptide
US4853871A (en) * 1987-04-06 1989-08-01 Genex Corporation Computer-based method for designing stablized proteins
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
GB2213821B (en) 1987-12-23 1992-01-02 British Bio Technology Synthetic human granulocyte colony stimulating factor gene
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
DE68918331T2 (de) 1988-06-03 1995-05-18 Chugai Pharmaceutical Co Ltd Menschlicher kristallinischer Granulocyt-Koloniestimulierungsfaktor und dessen Herstellung.
US5025388A (en) * 1988-08-26 1991-06-18 Cramer Richard D Iii Comparative molecular field analysis (CoMFA)
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5104651A (en) 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
US20020177688A1 (en) 1988-12-22 2002-11-28 Kirin-Amgen, Inc., Chemically-modified G-CSF
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US6166183A (en) * 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5109119A (en) 1989-06-06 1992-04-28 Schering Corporation Crystalline r-h-gm-csf and method
IE66494B1 (en) * 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
US5265030A (en) 1990-04-24 1993-11-23 Scripps Clinic And Research Foundation System and method for determining three-dimensional structures of proteins
GB9107846D0 (en) * 1990-04-30 1991-05-29 Ici Plc Polypeptides
US5399345A (en) * 1990-05-08 1995-03-21 Boehringer Mannheim, Gmbh Muteins of the granulocyte colony stimulating factor
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
DK0546124T4 (da) 1990-08-29 2003-05-19 Inst Genetics Llc Hæmatopoiese-stimulatorer med flere domæner
US5124297A (en) 1990-12-07 1992-06-23 Amoco Corporation Olefin polymerization and copolymerization catalyst
DE4105480A1 (de) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
DE69233336T2 (de) 1991-02-26 2005-03-31 Astrazeneca Ab Vektor
US5157736A (en) * 1991-04-19 1992-10-20 International Business Machines Corporation Apparatus and method for optical recognition of chemical graphics
ATE196548T1 (de) 1991-05-10 2000-10-15 Genentech Inc Auswählen von agonisten und antagonisten von liganden
AU2408292A (en) 1991-07-11 1993-02-11 Regents Of The University Of California, The A method to identify protein sequences that fold into a known three-dimensional structure
US5386507A (en) * 1991-07-18 1995-01-31 Teig; Steven L. Computer graphics system for selectively modelling molecules and investigating the chemical and physical properties thereof
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
ATE173763T1 (de) * 1991-08-30 1998-12-15 Hutchinson Fred Cancer Res Hybride cytokine
JP2638359B2 (ja) 1991-11-26 1997-08-06 富士通株式会社 分子動力学法の拘束条件作成装置
JPH08507916A (ja) 1992-06-09 1996-08-27 カイロン コーポレイション Ｍ−ｃｓｆの結晶化
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
CA2150117A1 (en) 1992-11-24 1994-06-09 S. Christopher Bauer Interleukin-3 (il-3) mutant polypeptides
US5772992A (en) 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
US6153183A (en) 1992-11-24 2000-11-28 G. D. Searle & Company Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US6057133A (en) * 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US5424963A (en) * 1992-11-25 1995-06-13 Photon Research Associates, Inc. Molecular dynamics simulation method and apparatus
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
JP2720140B2 (ja) * 1993-02-03 1998-02-25 日東化学工業株式会社 フェニル基を有する光学活性α−ヒドロキシカルボン酸の製造法
US6245900B1 (en) 1994-02-23 2001-06-12 Kyowa Hakko Kogyo Co., Ltd. Platelet production promoting agent
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
US5576941A (en) * 1994-08-10 1996-11-19 York Technologies, Inc. Modular power supply system
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
EP0807181A1 (de) 1995-02-03 1997-11-19 G.D. Searle & Co. Neue c-mpl liganden
US6017523A (en) 1995-06-06 2000-01-25 G.D. Searle & Co. Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
EP0870027A1 (de) 1995-10-05 1998-10-14 G.D. Searle & Co. C-mpl rezeptoragonisten
US6066318A (en) * 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
US6100070A (en) * 1995-10-05 2000-08-08 G. D. Searle & Co. G-CSF receptor agonists
KR100456212B1 (ko) 1995-10-05 2005-01-15 지.디. 썰 엘엘씨 다기능성조혈수용체아고니스트
US6660257B1 (en) 1996-10-25 2003-12-09 Pharmacia Corporation Circular permuteins of flt3 ligand
US5969105A (en) 1996-10-25 1999-10-19 Feng; Yiqing Stem cell factor receptor agonists
EP0935663A2 (de) 1996-10-25 1999-08-18 G.D. SEARLE & CO. Multifunktionelle agonisten des chimären hämatopoetischen rezeptors
CA2284127A1 (en) 1997-04-11 1998-10-22 G.D. Searle & Co. Flt3 ligand chimeric proteins
AU744085B2 (en) 1997-06-06 2002-02-14 Kyowa Hakko Kirin Co., Ltd. Chemically modified polypeptides
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
DE69920002T2 (de) 1998-04-28 2005-09-22 Applied Research Systems Ars Holding N.V. Konjugate aus polyole und beta-interferon
US6451986B1 (en) * 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
WO2000018905A1 (en) 1998-09-25 2000-04-06 G.D. Searle & Co. Method of producing permuteins by scanning permutagenesis
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
JP2000319298A (ja) 1999-03-04 2000-11-21 Seibutsu Bunshi Kogaku Kenkyusho:Kk 蛋白質複合体の結晶、構造座標、及び構造座標の使用
KR100356140B1 (ko) 1999-07-08 2002-10-19 한미약품공업 주식회사 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
DE60139110D1 (de) * 2000-01-10 2009-08-13 Maxygen Holdings Ltd G-csf konjugate
US20040254351A1 (en) 2000-09-07 2004-12-16 Beals John Michael Hyperglycosylated polypeptides
US6946548B2 (en) 2000-09-08 2005-09-20 Massachusetts Institute Of Technology G-CSF analog compositions and methods
GB0022877D0 (en) 2000-09-18 2000-11-01 Isis Innovation Analogues
AU2002212108A1 (en) * 2000-11-02 2002-05-15 Maxygen Aps Single-chain multimeric polypeptides
US20020142964A1 (en) * 2000-11-02 2002-10-03 Nissen Torben Lauesgaard Single-chain polypeptides

Also Published As

Publication number Publication date
WO2003006501A3 (en) 2004-03-25
US20060286069A1 (en) 2006-12-21
EP1425304B9 (de) 2010-09-08
US20110020266A1 (en) 2011-01-27
US20060286068A1 (en) 2006-12-21
EP1425304B1 (de) 2010-05-26
US7696153B2 (en) 2010-04-13
CA2452582C (en) 2013-01-22
US7550565B2 (en) 2009-06-23
US20070010660A1 (en) 2007-01-11
KR100961859B1 (ko) 2010-06-09
NO20040093L (no) 2004-03-09
IL159524A0 (en) 2004-06-01
JP2005506317A (ja) 2005-03-03
JP4444652B2 (ja) 2010-03-31
KR20040084884A (ko) 2004-10-06
HUP0400466A2 (hu) 2005-01-28
NZ530545A (en) 2006-10-27
WO2003006501A2 (en) 2003-01-23
AU2002325819B2 (en) 2008-06-19
BR0211071A (pt) 2004-12-21
EP1425304A2 (de) 2004-06-09
US7550566B2 (en) 2009-06-23
ATE468862T1 (de) 2010-06-15
PL371781A1 (en) 2005-06-27
CA2452582A1 (en) 2003-01-23
HUP0400466A3 (en) 2006-01-30
MXPA04000231A (es) 2004-05-04

Similar Documents

Publication Publication Date Title
DE60236522D1 (de) G-csf konjugate
EA004789B9 (ru) Полимерные конъюгаты бета-1а-интерферона и их использование
DK1180121T3 (da) Langtidsvirkende insulinotrope peptider
BR9910251A (pt) Estimulação hematopoiética
LU92175I2 (fr) Lixisénatide
ITMI20061624A1 (it) Mono-coniugati sito-specifici di g-csf
PT786257E (pt) Variantes de glicosilacao do activador de plasminogenio tissular com propriedades terapeuticas meloradas
HK1074855A1 (en) Glycoprotein synthesis
ATE399020T1 (de) Erythropoietin reduziert die chemotherapiebedingte in-vivo-toxizität
SG149685A1 (en) Polymer conjugates of neublastin and methods of using same
NO984052L (no) Rekombinante, adenovirale vektorer for human tumorgenterapi
CA2373252A1 (en) Long lasting anti-angiogenic peptides
IL130526A0 (en) Novel anti-allergenic agents

Legal Events

Date Code Title Description
8363 Opposition against the patent